Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 32, 06 March 2024
Open
Access | Article
Syphilis and advancements in its treatment
* Author to whom correspondence should be addressed.
Abstract
Syphilis is an infectious disease caused by the bacterium Treponema pallidum. Pallidum and its subspecies is a spirochete microaerophilic virus that sensitive to oxygen and temperature. T. pallidum is responsible for causing syphilis through sexual exposure and vertical transmission from pregnant women to their fetuses. The invasiveness and immunoevasiveness of syphilis is caused by its lack of outer membrane immune targets and with fewer surface transmembrane protein. These features explain why syphilis causes millions of people suffered from this disease and the incidence is still increasing. For the four stages of syphilis, there are different symptoms and courses of treatment approach should be taken. The administration of penicillin has reached a level of maturity and clarity in its therapeutic application. An alternative way of treatment involves the utilization of DNA vaccine. The more refined DNA vaccine technic suggests potential utility of the DNA vaccine in T.pallidum treatment. Furthermore, this review explores the current study on vaccine mRNA which holds substantial promise as a valuable avenue for syphilis treatment. T.pallidum, syphilis, transmission .
Keywords
syphilis, treatment, vaccine, T.pallidum
References
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015 Dec 8;10(12):e0143304. doi: 10.1371/journal.pone.0143304. PMID: 26646541; PMCID: PMC4672879.
2. Simms I, Fenton KA, Ashton M, Turner KM, Crawley-Boevey EE, Gorton R, Thomas DR, Lynch A, Winter A, Fisher MJ, Lighton L, Maguire HC, Solomou M. The re-emergence of syphilis in the United Kingdom: the new epidemic phases. Sex Transm Dis. 2005 Apr;32(4):220-6. doi: 10.1097/01.olq.0000149848.03733.c1. PMID: 15788919
3. Stamm LV. Syphilis: antibiotic treatment and resistance. Epidemiol Infect. 2015 Jun;143(8):1567-74. doi: 10.1017/S0950268814002830. Epub 2014 Oct 31. PMID: 25358292; PMCID: PMC9507240.
4. Lee V, Kinghorn G. Syphilis: an update. Clin Med (Lond). 2008 Jun;8(3):330-3. doi: 10.7861/clinmedicine.8-3-330. PMID: 18624050; PMCID: PMC4953845.
5. Gjestland T. The Oslo study of untreated syphilis; an epidemiologic investigation of the natural course of the syphilitic infection based upon a re-study of the Boeck-Bruusgaard material. Acta Derm Venereol Suppl (Stockh). 1955;35(Suppl 34):3-368; Annex I-LVI. doi: 10.2340/00015555343368. PMID: 13301322
6. Morales-Múnera CE, Fuentes-Finkelstein PA, Vall Mayans M. Update on the diagnosis and treatment of syphilis. Actas Dermosifiliogr. 2015 Jan-Feb;106(1):68-9. English, Spanish. doi: 10.1016/j.ad.2014.06.007. Epub 2014 Sep 20. PMID: 25245171.
7. Zhang X, Zhao T, Zeng T, Wu N, Xiao Y, Liu S, Yu J, Jiang C, Gan L, Deng M, Luo X, Zhao F. Intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 and enhanced immunization with mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein effectively induced strong mucosal immune responses and immune protective effects against Treponema pallidum skin infection. Exp Ther Med. 2018 Mar;15(3):2533-2540. doi: 10.3892/etm.2018.5689. Epub 2018 Jan 4. PMID: 29456657; PMCID: PMC5795528
8. Maruggi G, Chiarot E, Giovani C, Buccato S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G, Maione D. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine. 2017 Jan 5;35(2):361-368. doi: 10.1016/j.vaccine.2016.11.040. Epub 2016 Dec 7. PMID: 27939014.
9. Radolf JD, Norgard MV, Schulz WW. Outer membrane ultrastructure explains the limited antigenicity of virulent Treponema pallidum. Proc Natl Acad Sci U S A. 1989 Mar;86(6):2051-5. doi: 10.1073/pnas.86.6.2051. PMID: 2648388; PMCID: PMC286845.
10. Cox DL, Chang P, McDowall AW, Radolf JD. The outer membrane, not a coat of host proteins, limits antigenicity of virulent Treponema pallidum. Infect Immun. 1992 Mar;60(3):1076-83. doi: 10.1128/iai.60.3.1076-1083.1992. PMID: 1541522; PMCID: PMC257596.
11. Salazar JC, Hazlett KR, Radolf JD. The immune response to infection with Treponema pallidum, the stealth pathogen. Microbes Infect. 2002 Sep;4(11):1133-40. doi: 10.1016/s1286-4579(02)01638-6. PMID: 12361913.
12. Koundanya VV, Tripathy K. Syphilis Ocular Manifestations. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32644383.
13. Weinstock GM, Hardham JM, McLeod MP, Sodergren EJ, Norris SJ. The genome of Treponema pallidum: new light on the agent of syphilis. FEMS Microbiol Rev. 1998 Oct;22(4):323-32. doi: 10.1111/j.1574-6976.1998.tb00373.x. PMID: 9862125.
14. Centurion-Lara A, Castro C, Barrett L, Cameron C, Mostowfi M, Van Voorhis WC, Lukehart SA. Treponema pallidum major sheath protein homologue Tpr K is a target of opsonic antibody and the protective immune response. J Exp Med. 1999 Feb 15;189(4):647-56. doi: 10.1084/jem.189.4.647. Erratum in: J Exp Med 1999 Jun 7;189(11): 1852. PMID: 9989979; PMCID: PMC2192927.
15. Centurion-Lara A, LaFond RE, Hevner K, Godornes C, Molini BJ, Van Voorhis WC, Lukehart SA. Gene conversion: a mechanism for generation of heterogeneity in the tprK gene of Treponema pallidum during infection. Mol Microbiol. 2004 Jun;52(6):1579-96. doi: 10.1111/j.1365-2958.2004.04086.x. PMID: 15186410.
16. Radolf JD. Role of outer membrane architecture in immune evasion by Treponema pallidum and Borrelia burgdorferi. Trends Microbiol. 1994 Sep;2(9):307-11. doi: 10.1016/0966-842x(94)90446-4. PMID: 7812663.
17. Harmon, Elizabeth D. DNP, APRN, FNP-BC; Robertson, Eric Wayne DNP, RN. Syphilis: A growing concern. The Nurse Practitioner 44(8):p 21-28, August 2019. | DOI: 10.1097/01.NPR.0000558159.61349.cb
18. CUMBERLAND MC, TURNER TB. The rate of multiplication of Treponema pallidum in normal and immune rabbits. Am J Syph Gonorrhea Vener Dis. 1949 May;33(3):201-12. PMID: 18121293.
19. Stokes, J. H., H. Beerman, and N. R. Ingraham. 1944. Modern clinical syphilology. The W.B. Saunders Co., Philadelphia, Pa.
20. Mahoney, J. F., K. K. Bryant. 1934. The time element in the penetration of the genital mucosa of the rabbit by the Treponema pallidum. Vener. Dis. Inf. 15:1-5.
21. Magnuson HJ, Thomas EW, Olansky S, Kaplan BI, De Mello L, Cutler JC. Inoculation syphilis in human volunteers. Medicine 1965
22. Podwinska J, Lusiak M, Zaba R, Bowszyc J. The pattern and level of cytokines secreted by Th1 and Th2 lymphocytes of syphilitic patients correlate to the progression of the disease. FEMS Immunol Med Microbiol. 2000 May;28(1):1-14. doi: 10.1111/j.1574-695X.2000.tb01451.x. PMID: 10767602.
23. Van Voorhis WC, Barrett LK, Koelle DM, Nasio JM, Plummer FA, Lukehart SA. Primary and secondary syphilis lesions contain mRNA for Th1 cytokines. J Infect Dis. 1996 Feb;173(2):491-5. doi: 10.1093/infdis/173.2.491. PMID: 8568320.
24. Hourihan M, Wheeler H, Houghton R, Goh BT. Lessons from the syphilis outbreak in homosexual men in east London. Sex Transm Infect. 2004 Dec;80(6):509-11. doi: 10.1136/sti.2004.011023. PMID: 15572625; PMCID: PMC1744940.
25. Mindel A, Tovey SJ, Timmins DJ, Williams P. Primary and secondary syphilis, 20 years’ experience. 2. Clinical features. Genitourin Med. 1989 Jan;65(1):1-3. doi: 10.1136/sti.65.1.1. PMID: 2921046; PMCID: PMC1196177.
26. Rompalo AM, Joesoef MR, O’Donnell JA, Augenbraun M, Brady W, Radolf JD, Johnson R, Rolfs RT; Syphilis and HIV Study Group. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis. 2001 Mar;28(3):158-65. doi: 10.1097/00007435-200103000-00007. PMID: 11289198
27. Hutchinson CM, Hook EW 3rd, Shepherd M, Verley J, Rompalo AM. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med. 1994 Jul 15;121(2):94-100. doi: 10.7326/0003-4819-121-2-199407150-00003. PMID: 7912483
28. Chapel TA. The signs and symptoms of secondary syphilis. Sex Transm Dis. 1980 Oct-Dec;7(4):161-4. doi: 10.1097/00007435-198010000-00002. PMID: 7455863.
29. Hira SK, Patel JS, Bhat SG, Chilikima K, Mooney N. Clinical manifestations of secondary syphilis. Int J Dermatol. 1987 Mar;26(2):103-7. doi: 10.1111/j.1365-4362.1987.tb00532.x. PMID: 3570579.
30. Greenstein DB, Wilcox CM, Schwartz DA. Gastric syphilis. Report of seven cases and review of the literature. J Clin Gastroenterol. 1994 Jan;18(1):4-9. PMID: 8113584.
31. Mullick CJ, Liappis AP, Benator DA, Roberts AD, Parenti DM, Simon GL. Syphilitic hepatitis in HIV-infected patients: a report of 7 cases and review of the literature. Clin Infect Dis. 2004 Nov 15;39(10):e100-5. doi: 10.1086/425501. Epub 2004 Oct 26. PMID: 15546070.
32. Fehér J, Somogyi T, Timmer M, Józsa L. Early syphilitic hepatitis. Lancet. 1975 Nov 8;2(7941):896-9. doi: 10.1016/s0140-6736(75)92129-7. PMID: 53374..
33. Wijesooriya NS, Rochat RW, Kamb ML, Turlapati P, Temmerman M, Broutet N, Newman LM. Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study. Lancet Glob Health. 2016 Aug;4(8):e525-33. doi: 10.1016/S2214-109X(16)30135-8. PMID: 27443780; PMCID: PMC6759483.
34. Sexually Transmitted Infections Treatment Guidelines, 2021: Congenital syphilis. [ Nov; 2022 ]. 2021. https://www.cdc.gov/std/treatment-guidelines/congenital-syphilis.htm
35. Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics; 2021
36. Zhao F, Liu S, Zhang X, Yu J, Zeng T, Gu W, Cao X, Chen X, Wu Y. CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits. Hum Vaccin Immunother. 2013 Apr;9(4):753-60. doi: 10.4161/hv.23064. Epub 2013 Apr 1. PMID: 23563515; PMCID: PMC3903891
37. Blakney AK, Ip S, Geall AJ. An Update on Self-Amplifying mRNA Vaccine Development. Vaccines (Basel). 2021 Jan 28;9(2):97. doi: 10.3390/vaccines9020097. PMID: 33525396; PMCID: PMC7911542.
38. Sharma R, Rajput VS, Jamal S, Grover A, Grover S. An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins. Sci Rep. 2021 Jul 5;11(1):13836. doi: 10.1038/s41598-021-93266-w. Erratum in: Sci Rep. 2021 Aug 13;11(1):16844. PMID: 34226593; PMCID: PMC8257786.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-321-0
- ISBN (Online)
- 978-1-83558-322-7
- Published Date
- 06 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/32/20240644
- Copyright
- 06 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited